Calendario›REGN›Fianlimab+cemiplimab

Fianlimab+cemiplimab

A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

Ensayo de REGENERON PHARMACEUTICALS, INC. en Melanoma.

Más ensayos de: Melanoma.

Fase

Fase 2

Estado

Reclutando por invitación

Participantes

48

previstos

Centros

11

Fin del objetivo primario

oct 2029

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en abr 2025.

Qué mide

Death from any cause starting at time of initial treatment with fianlimab and cemiplimab in study R3767-ONC-1613 (del registro, en inglés) (hasta 4 años)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching the long-term effects of a combination of experimental drugs called fianlimab and cemiplimab. The study is being conducted in patients with advanced skin cancer (melanoma) who had previously been treated with fianlimab and cemiplimab in the study called R3767-ONC-1613 (NCT03005782). The aim of the current study is to see how safe and effective the study drugs are in a long-term follow-up. No study drug will be given during this study. Cancer status will be monitored, in addition to routine care. The study is also collecting information about general health status, and other treatments that may have been received since participation in study R3767-ONC-1613 (NCT03005782).

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06848088), actualizada en jul 2026.